By Mike Stobbe
A month after federal officials recommended new versions of COVID-19 vaccines, 7% of U.S. adults and 2% of children have gotten a shot.
One expert called the rates “abysmal.”
The numbers, presented Thursday at a meeting held by the Centers for Disease Control and Prevention, come from a national survey of thousands of Americans, conducted two weeks ago.
The data also indicated that nearly 40% of adults said they probably or definitely will not get the shot. A similar percentage of parents said they did not plan to vaccinate their children.
In the late summer, government health officials made the nation's COVID-19 vaccination campaign more like the annual flu campaign.
Officials approved updated shots that have a single target, an omicron descendant named XBB.1.5. They replaced vaccines that targeted the original coronavirus strain and a much earlier omicron version. Last month, the CDC recommended the new shots for everyone 6 months and older.
The government also transitioned to a commercialized system that relied on the health-care industry — not the government — to handle the distribution of the shots. Many people who immediately went for shots said pharmacies or doctors didn't have them.
Americans have been urged to get different iterations of the vaccines for more than 2/12 years. This year, COVID-19 deaths and hospitalizations fell to lower levels than seen in the previous three years.
Cases remain low compared with the pandemic's early months. Even so, health officials say about 18,000 hospitalization and 1,200 deaths are still being reported each week.
One expert at the meeting, Dr. Camille Kotton of Harvard Medical School, called the numbers “abysmal” and said part of the problem may be patient confusion. She urged stepped-up public education efforts.
Dr. David Kimberlin, of the University of Alabama at Birmingham, also expressed dismay.
“The recommendations are not being heard," he said.
The sophisticated rocket sent a payload that included 24 satellites, a new, solar-powered space sail, and the ashes of 152 people, into space with its side boosters successfully returning to Earth unscathed.
That next step for meat alternatives will apparently include fish as companies like Wild Type, BlueNalu, and Finless Foods wager that, in the age of plant-based burgers, there’s room for seafood grown in the lab.
These are the headlines you Need 2 Know for Wednesday, June 19, 2019.
Elon Musk may be going to Vegas. The Las Vegas Convention and Visitors Authority has recommended that The Boring Company be chosen to construct a "people mover" below the expanding convention center.
Cannabis, hemp, reefer, marijuana, dope, pot, grass ー no matter what term you choose, they all refer to the same plant: cannabis sativa. It’s a common misconception that cannabis sativa exclusively means that particular strain of weed that makes you creative and focused (as opposed to indica, which promotes relaxation)ー but it’s actually the scientific name of the single plant that yields marijuana, CBD, and hemp, among other products.
These are the headlines you Need 2 Know for Tuesday, Feb. 19, 2019.
Canopy Growth CEO Bruce Linton won't guarantee investors dividends. What he will promise is a stake in global cannabis domination. "If people want a dividend, we are probably not the right stock. If they want some entity aimed at dominating a global opportunity that started in Canada, we are probably your best bet," Linton told Cheddar on Friday, one day after the company reported a massive spike in third-quarter revenue.
These are the headlines you Need 2 Know for Friday, Feb, 15, 2019.
It's a big week in cannabis earnings ー Aurora Cannabis reported Monday and Canopy Growth will report Thursday ー but Paul Rosen, CEO of cannabis private equity firm Tidal Royalty, said he's noticing a concerning trend."All the companies are facing gross margin compression because there are excise taxes, there's a massive marketing spend as we go to recreational cannabis, and there's also increased packaging costs. So I think you're going to see a trend line here, which is revenue and capacity going up, but gross margin is going down," Rosen told Cheddar Wednesday.
Opiant Pharmaceuticals, the developer of opioid antidote NARCAN, is in the process of developing a version of its lifesaving drug for cannabanoid overdoses, the company's CEO told Cheddar in an interview on Wednesday.
